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Abstract
Background—The variety of LC-MS/MS methods measuring total 25(OH)D used today is vast 
and the comparability among these methods is still not well assessed.
Methods—Here, we performed a comparison in samples of healthy donors between the currently 
routinely used 25(OH)D LC-MS/MS methods in the Netherlands and the Ghent University 
reference measurement procedure to address this issue (n = 40). Additionally, an interlaboratory 
comparison in patient serum samples assessed agreement between the Dutch diagnostic methods 
(n = 37).
Results—The overall correlation of the routine methods for 25(OH)D3 with the reference 
measurement procedures and with the mean of all diagnostic methods was excellent (r > 0.993 and 
r > 0.989, respectively). Three out of five methods aligned perfectly with both the reference 
measurement procedure and the median of all methods. One of the routine methods showed a 
small positive bias, while another showed a small negative bias consistently in both comparisons.
Conclusion—The biases most probably originated from differences in calibration procedure and 
may be obviated by reassessing calibration of stock standards and/or calibrator matrices. In 
conclusion, five diagnostic centers have performed a comparison with the 25(OH)D Ghent 
University reference measurement procedure in healthy donor serum samples and a comparison 
among themselves in patient serum samples. Both analyses showed a high correlation and 
specificity of the routine LC-MS/MS methods, yet did reveal some small standardization issues 
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that could not be traced back to the technical details of the different methods. Hence, this study 
indicates various calibration procedures can result in perfect alignment.
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1. Introduction
Assessment of Vitamin D status in patients relies on accurate measurement of 25-
hydroxyvitamin D (25(OH)D) concentration in serum or plasma, which can be achieved 
through appropriate standardization [2]. In a joined effort to implement standardized 
measurements for 25(OH)D, the National Institute of Health (NIH), the US Center for 
Disease Control and Prevention (CDC), the US National Institute of Standards and 
Technology (NIST) and the Belgian Laboratory for Analytical Chemistry in Ghent 
(UGhent), in collaboration with other researchers and organizations, established the Vitamin 
D Standardization Program (VDSP) [9]. The goal of this collaboration is to make 25(OH)D 
measurements traceable to the highest order reference, the NIST Standard Reference 
Material 2972a, by using recognized reference measurement procedures (RMP) operated at 
NIST, CDC, and UGhent and high quality serum based reference materials with values 
assigned by these RMPs [8, 10,11]. Although several immunoassays and liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) assays have been standardized by 
CDC’s Vitamin Standardization Certification Program [1], information about the accuracy 
of routinely used liquid chromatography-tandem mass spectrometry (LC-MS/MS) 25(OH)D 
methods is very limited. Since LC-MS/MS methods are known to generate more specific 
and accurate measurements than immunoassay-based methods, many laboratories have 
implemented this technique for patient assessment [4–6]. While in theory all LC-MS/MS 
based methods should deliver similar results, the actual procedures for preparing samples, 
standards or operating the instruments can be vastly different which leads to differences in 
measurement accuracy and performance. To address this matter, we performed a method 
comparison study between the currently used routine 25(OH)D LC-MS/MS methods in the 
Netherlands and the UGhent RPM using healthy donor serum samples and an inter-
laboratory method comparison to assess agreement between the different laboratories using 
routine patient serum samples.
2. Materials and methods
2.1. Samples
Forty single healthy donor serum samples from the CDC Vitamin D Standardization 
Certification Program (VDSCP) (so called ‘phase 1 samples’), which had been assigned a 
reference value by the UGhent RMP were used. These sera were obtained and processed 
according to CLSI protocol C37 [13] and covered a range of 23 to 198 nmol/L for 
25(OH)D3, < 1 to 14 nmol/L for 25(OH)D2, and 2 to 43 nmol/L for epi-25(OH)D3. In 
addition, 37 single patient donor serum samples were obtained by drawing an extra tube of 
blood from patients who already underwent a venipuncture for diagnostic purposes in our 
outpatient clinic (VU University Medical Center, Amsterdam). These patient sera had 
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concentrations ranging from <1 to 134 nmol/L for 25(OH)D3, < 2 to 27 nmol/L for 
25(OH)D2 and < 1 to 7 nmol/L for epi25(OH)D3 as determined by [12]. All samples were 
anonymized immediately after withdrawal and processed like regular patient samples. After 
centrifugation, serum was separated, aliquotted and frozen at −20 °C until analyses. Samples 
were distributed frozen on dry ice. Studies were approved by the local medical ethical 
committees.
2.2. Analytical methods
Five laboratories (the Radboud University Medical Center Nijmegen (Method A) (in 
duplicate), the University Medical Center Groningen (Method B) (in duplicate), the Canisius 
Wilhelmina Hospital in Nijmegen (Method C) (in singlicate), Medlon in Enschede (Method 
D) (in singlicate) and the VU University Medical Center in Amsterdam (Method E) (in 
duplicate) measured total 25(OH)D3 concentrations with their respective routine LC-MS/MS 
methods. Duplicate or singlicate measurements were based on the way routine patient 
samples are measured in each laboratory. Methods B, C and E measured 25(OH)D3 and 
25(OH)D2 while Method A and D only measured 25(OH)D3. Technical details of the 
measurement and calibration procedures are given in Tables 1 and 2, respectively. The 
characteristics of the UGhent RMP have been described elsewhere [10,11].
Ideally, the comparisons would be based on total 25(OH)D, which is defined as the sum of 
25(OH)D3 and 25(OH)D2. However, here we chose to compare the sum of 25(OH)D3 and 
epi-25(OH)D3 for the RMP and 25(OH)D3 for the routine LC-MS/MS 25(OH)D methods. 
We thus excluded 25(OH)D2 as it is rarely seen in patient samples in the Netherlands and 
two of the five routine 25(OH)D LC-MS/MS methods therefore do not include it in their 
routine measurements. Moreover, we included epi-25(OH)D3 for the RMP, because all 
Dutch routine LC-MS/MS 25(OH)D methods co-measure it with 25(OH)D3. By doing so 
we assured the optimal assessment of the routine Dutch LC-MS/MS 25(OH)D methods in 
clinical decision making.
2.3. Statistical analysis
25(OH)D3 concentrations, as determined by the five Dutch LC-MS/MS methods, were 
compared with the sum of 25(OH)D3 and epi-25(OH)D3 values obtained by the RMP for the 
healthy donor serum samples (n = 40). For the inter-laboratory comparison in patient serum 
samples (n = 37), the median of all 25(OH)D3 measurements was compared to the individual 
25(OH)D3 results.
Passing and Bablok regression analyses, Bland Altman plots and Pearson’s correlation 
coefficients were used to assess agreement in the method comparisons (MedCalc Software 
Ltd.).
3. Results
Healthy donor serum sample comparison of the five routine LC-MS/MS methods measuring 
25(OH)D3 to the UGhent RMP yielded the equations and Pearson’s correlation coefficients 
as depicted in Table 2. Figs. 1 and S1 show the corresponding Passing and Bablok regression 
analyses and Bland-Altman plots, respectively.
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Regression analysis showed significantly deviating slopes for methods B (9%) and D 
(−10%). Mean biases ranged from −9.59% to 7.20%. Sample specific biases, as expressed in 
the limits of agreement obtained from the bias plot analysis, ranged from ±10.63% to 
±20.64%. All routine methods showed excellent correlations with values above 0.993. 
Passing and Bablok regression analysis of the median values of all routine LC-MS/MS 
methods in the healthy donor serum samples with the RMP resulted in a slope of 1.00 and a 
small mean bias of 1.54%. Sample specific variation was also modest with ±7.60%. An 
optimal correlation of 1.000 was observed.
Results of the comparison of 25(OH)D3 concentrations in patient samples of the five LC-
MS/MS methods with the median of the measurements is shown in Fig. 2, Fig. S2 and Table 
3 and yielded analogous results. Here, only method D showed a significant proportional bias 
of −10%. Mean biases were observed ranging from −13.85% to 5.01%, while sample 
specific bias ranged from ±9.59% to ±45.36%. Again high correlations were observed (r ≥ 
0.989).
4. Discussion
In this study we assessed the agreement of five routine 25(OH)D LC-MS/MS methods for 
their measurement of 25(OH)D3. To this end we compared the results of these methods to 
the UGhent RMP using single healthy donor serum samples and to the median of all 
methods in patient sera from routine analysis.
To correctly evaluate agreement between the routine 25(OH)D LC-MS/MS methods with the 
RMP, routine method 25(OH)D3 results were compared with the sum of 25(OH)D3 and 
epi-25(OH)D3 for the RMP. Though normally total 25(OH)D (sum of 25(OH)D3 and 
25(OH)D2) would be used, we opted for this approach as 25(OH)D2 is rarely seen in Dutch 
patient samples and two of the five routine 25(OH)D LC-MS/MS methods therefore do not 
include it in their routine measurements. Furthermore, since the routine 25(OH)D methods 
co-measure epi-25(OH)D3 with their 25(OH)D3, we also summed 25(OH)D3 and 
epi-25(OH)D3 for the RMP. In the first comparison 9 samples contained measurable 
25(OH)D2 levels, which comprised on average 6% of the total 25(OH)D. All but two 
samples contained measurable epi-(OH)D3 levels, comprising on average 6% of the total 25-
(OH)D. The routine LC-MS/MS 25(OH)D methods not separating the 25(OH)D3 epimer 
will overestimate the sum of the 25(OH)D3 and epi-25(OH)D3 concentrations as the two 
show slightly different ionization intensities [12]. However, if the average epi-25(OH)D3 
concentration comprises 6% of the 25(OH)D3 levels and the difference in ionization 
intensity is 30–40%, this would mean an estimated positive bias of approximately 2% for the 
routine 25(OH)D methods, which can be considered clinically irrelevant. It is thought that 
only when measuring in infants, the epi-25(OH)D3 concentrations comprise high enough 
percentages of 25(OH)D3 to be of relevance in clinical decision making [7,14]. Though 
some reports suggests that the epi-25(OH)D3 concentration is not negligible in all adults 
[15,16]. All things considered, this study therefore focused on 25(OH)D3.
The 25(OH)D LC-MS/MS methods, correlated very well with the sum of 25(OH)D3 and 
epi-25(OH)D3 for the RMP (r ≥ 0.993) and with the median 25(OH)D3 results of the five 
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routine methods (r ≥ 0.989). This is in accordance with earlier LC-MS/MS comparisons for 
25(OH)D3 that have shown good correlations among themselves [4–6]. The comparison in 
patient donor serum was conducted to monitor any complications that may arise when 
measuring patient populations [3]. However, no such difficulties were observed, as evident 
from the agreement between the two sets of samples. Although all methods strongly 
correlated with the RMP, not all methods perfectly aligned with it. Both method B and D 
supposedly suffer from, albeit small, calibration issues as evident from the deviating slopes 
and reported mean biases in the Passing and Bablok regression analysis and the Bland-Alt-
man plots, respectively. For these two labs, mean biases exceeded the performance criterion 
of ±5% mean bias as drafted by the CDC. Similar findings were reported following the 
interlaboratory comparison, where the median values of all five laboratories served as 
reference. The use of the median as reference was justified, as is showed by the perfect 
alignment (slope of 1.00) and correlation (r = 1.000) with the RMP in the first comparison. 
In the interlaboratory comparison, Methods B and D again showed positive and negative 
slope deviations, respectively. For method B, the deviating slope was no longer significant. 
As expected, the correlation, although still very high, decreased slightly with this second 
comparison (r ≥ 0.989).
The observed differences may originate from the slightly different technical details as 
described in Table 1. Though, as all assays included the use of an internal standard, neither 
equipment nor technician handling should contribute to the discrepancy. Calibration or 
preparation of stock standards, however, may influence mean bias. The observed differences 
in sample specific biases, as represented by the limits of agreement, markedly differed 
between the routine methods. Variance in operation procedure and/or data processing may 
be causative for this. We performed a detailed analysis of the various calibration procedures 
performed by the five centers to assess if additional attention to avoid potential biases is 
required. Nonetheless we were unable to explain the observed biases from the technical 
details of any the routine methods. In fact, as Methods A, C and E show no uniformity in 
their technical details, yet show optimal alignment and excellent correlation in both 
comparisons, proper calibration is possible through multiple means, without one preferable 
over the other. Hence, other potential sources of bias need to be investigated.
In conclusion, five diagnostic centers measuring total 25(OH)D have performed a 
comparison for 25(OH)D3 with the UGhent RMP in healthy donor serum samples and a 
comparison among themselves in patient serum samples. Both analyses showed a high 
correlation and specificity of LC-MS/MS methods, yet did reveal some small 
standardization issues that could not be traced back to the technical details of the different 
methods. Hence, this study indicates various calibration procedures can result in perfect 
alignment with the RMP.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Passing and Bablok regression analyses of the five routine 25(OH)D LC-MS/MS methods 
measuring 25(OH)D3 in healthy donor serum samples and the median compared to the 
results obtained by the RMP (sum of 25(OH)D3 and epi-25(OH)D3). Middle dotted line 
represents y = x, outer dotted lines represent 95% confidence interval. RMP, reference 
measurement procedure.
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Fig. 2. 
Passing and Bablok regression analyses of the five routine LC-MS/MS methods measuring 
25(OH)D3 in patient serum samples compared to median of all methods. Middle dotted line 
represents y = x, outer dotted lines represent 95% confidence interval.
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